Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.54 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5687830 | 0.88 | ALOX5 (0.55) | CYP4F2CYP4A11ALOX5ALDH1A1 | |
| SCHEMBL491004 | 0.86 | CYP4F2 (0.57) | CYP4F2CYP4A11CYP4Z1ALOX5CYP1A2 | |
| SCHEMBL3799726 | 0.86 | CYP4F2 (0.50) | CYP4F2CYP4A11CYP4Z1ALOX5CYP1A2 | |
| SCHEMBL17185943 | 0.84 | CYP4F2 (0.55) | CYP4F2CYP4A11CYP4Z1CYP1A2LMNA | |
| SCHEMBL7857817 | 0.83 | CYP4F2 (0.57) | CYP4F2CYP4A11CYP4Z1CYP1A2LMNA | |
| SCHEMBL16049167 | 0.83 | RPS6KA3 (0.45) | ALOX5LMNAALDH1A1GAAHSD17B10 | |
| SCHEMBL889921 | 0.83 | CYP4F2 (0.57) | CYP4F2CYP4A11CYP4Z1ALOX5APP | |
| SCHEMBL17197084 | 0.83 | CYP4F2 (0.50) | CYP4F2CYP4A11CYP4Z1CYP1A2LMNA | |
| SCHEMBL2347025 | 0.83 | CYP4F2 (0.58) | CYP4F2CYP4A11CYP4Z1ALOX5APP | |
| SCHEMBL6913578 | 0.82 | CYP4F2 (0.61) | CYP4F2CYP4A11CYP4Z1APPPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254647-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2022-02-22 | — | — | US | disclosed |
| US-11230526-B1 | Cylcoalkenyl derivatives useful as agonists of the GPR120 and/or GPR40 receptors | JANSSEN PHARMACEUTICA NV (BE) | 2022-01-25 | — | — | US | disclosed |
| EP-3409671-B1 | ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2021-07-21 | — | — | EP | disclosed |
| EP-3421458-B1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-11 | — | — | EP | disclosed |
| US-20200317629-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-08 | — | — | US | disclosed |
| US-10730847-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-04 | — | — | US | disclosed |
| US-10618893-B2 | GPR120 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICALS NV (BE) | 2020-04-14 | — | — | US | disclosed |
| CN-106414434-B | Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes | 詹森药业有限公司 | 2019-12-31 | — | — | CN | disclosed |
| CN-106061943-B | It can be used as the bicyclic pyrrole derivatives of the agonist of GPR120 | 詹森药业有限公司 | 2019-11-05 | — | — | CN | disclosed |
| WO-2019171277-A1 | CYLCOALKENYL DERIVATIVES USEFUL AS AGONISTS OF THE GPR120 AND /OR GPR40 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-12 | — | — | WO | disclosed |
| US-20100216827-A1 | ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100190831-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190831-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190831-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2010-07-29 | — | — | US | disclosed |
| WO-2010080537-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010080537-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010048207-A2 | ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010048207-A2 | ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| US-20080167378-A1 | Receptor Function Regulation Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1688138-A1 | RECEPTOR FUNCTION REGULATING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2006-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167378-A1 | Receptor Function Regulation Agent | GPR119, INSR, GPR88 | CYP4F2 1295/4885CYP4A11 773/4885CYP4Z1 1911/4885 |
| US-20200317629-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | GPR119, GPR180, GPR55 | CYP4F2 1133/4885CYP4A11 1112/4885CYP4Z1 3064/4885 |
| US-20100190831-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | CYP4F2 1483/4885CYP4A11 1325/4885CYP4Z1 3130/4885 |
| US-11230526-B1 | Cylcoalkenyl derivatives useful as agonists of the GPR120 and/or GPR40 receptors | GPR119, GPR65, GPR55 | CYP4F2 2530/4885CYP4A11 1061/4885CYP4Z1 3141/4885 |
| US-10618893-B2 | GPR120 agonists for the treatment of type II diabetes | GPR119, GLP1R, GCGR | CYP4F2 2590/4885CYP4A11 631/4885CYP4Z1 4327/4885 |
| US-11254647-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | GPR119, GPR180, GPR55 | CYP4F2 1133/4885CYP4A11 1112/4885CYP4Z1 3064/4885 |
| US-20100216827-A1 | ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | CYP4F2 672/4885CYP4A11 719/4885CYP4Z1 1778/4885 |
| US-10730847-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | GPR119, GPR180, GPR55 | CYP4F2 1133/4885CYP4A11 1112/4885CYP4Z1 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.